We take a look at directors buying and selling shares in their own company in our weekly column.
- 3i Group director buys 14,075 shares
- Arix Bioscience Chairman buys 200k shares
- Unbound non-exec buys 416k shares
- Aquila European Renewables board members purchase shares
- Brave Bison CFO buys 200k shares
3i Group LON:III Director David Hutchison has purchased on 6th February 14,075 shares at a price of 1,634.5p for a total consideration of £230,056. This follows Director Jasi Halai who, on 31st January purchased 3,168 shares at 1,570p for a total consideration of £49,738. The FTSE100 listed private equity and venture capital company recently updated the markets on Q3 performance noting that the “Private Equity and Infrastructure portfolio continues to demonstrate its resilience in challenging trading conditions” and stating that it was on track to deliver ‘another year of good growth” having started the new year “with good momentum across all ten of its geographic markets”.
At the time of writing, shares were trading at 1,631.50p, an increase of 22% on the year to date and up 21% over last 12 months.
Arix Bioscience LON:ARIX Chairman, Peregrine Moncreiffe has purchased 200,000 shares in the Company on 06 February 2023 at a price of 108.5p per share for a total consideration of £217,000. The venture capital company is focused on investing in breakthrough biotechnology companies around cutting edge advances in life sciences recently announced the acquisition of Twelve Bio, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines for $85m.
Shares were trading at 109.5p at the time of writing, up 2% on the year to date and -7% on the last 12 months.
Unbound Group [LON:UBG] Non-Executive Director, Alastair Miller purchased 416,396 shares on 6th February at a price of 4.8p per share for a total cost of £20,083. The AIM listed company is engaged in selling a range of brands focused on the over 55 age demographic and undertook a fundraise in June of last year in order to “accelerate its growth strategy and boost profitability”. The company recently provided a trading update to the market noting disappointing trading in the second half, citing “weakened demand from the current economic slowdown” and the business will focus will remain on managing costs, protecting margins and cashflow as it navigates the challenging economic conditions.
At the time of writing, shares were trading at 5.12p, down 34% on the year to dat and -90% over the last 12 months.
- Brave Bison beats expectations with 2024 growth
- Top Investment Trusts of 2024
- Brave Bison bets on Engage Digital
Aquila European Renewables [LON:AERS] Chairman, Ian Nolan has bought 50,000 shares in the Company at an average price of €0.907 for a total consideration of €45,373. On the same day, Non Executive Director purchased 50,000 shares at a price of €0.90708 for a total consideration of €45,354. The investment company manages a diversified portfolio of wind, solar photovoltaic and hydropower investments across continental Europe and Ireland and has recently announced an increased dividend of 5.51cents, up 5% on 2022 and a Share Buyback Programme for up to EUR 20 million, designed to boost the share price to more accurately “reflect the inherent value in the portfolio”.
Shares were trading at 82.18p, up 1.5% for the year to date and -5% over the last 12 months.
Brave Bison LON:BBSN Chief Financial Officer, Philippa Norridge has purchased 199,522 shares in the Company at a price of 2.5p per share for a total consideration of £4,988. The social and digital media company announced in their interim trading statement back in July that on the back of record operating profits, it expected to report a better full year than expected. The company is pursuing an acquisition strategy and recently purchased Social Chain Limited, a social media and influencer marketing agency, for an initial consideration of £7.7m.
Shares were trading at 2.7p at the time of writing, up 20% for the year to date and +54% over the last 12 month period.
Here’s why Director Dealings can play an important role in stock-picking